Article
Biochemistry & Molecular Biology
Sophie Mouillet-Richard, Severine Martin-Lanneree, Delphine Le Corre, Theo Z. Hirsch, Alexandre Ghazi, Marine Sroussi, Camilla Pilati, Aurelien de Reynies, Fatima Djouadi, Nicolas Vodovar, Jean-Marie Launay, Pierre Laurent-Puig
Summary: The cellular prion protein PrPC and caveolin-1 (CAV1) have been found to interact in neurodegenerative diseases and cancer. This study uncovers the molecular link between PrPC and CAV1 in cancer, showing that PrPC regulates CAV1 expression and interacts with it. PrPC also controls the expression of other proteins related to Alzheimer's disease and regulates the levels of A beta.
Article
Oncology
Chul-Won Yun, Jun-Hee Lee, Gyeongyun Go, Juhee Jeon, Sungtae Yoon, Sang-Hun Lee
Summary: Cellular prion protein (PrP(C)) is overexpressed in cancers and plays a role in cancer proliferation, invasion, metastasis, and drug resistance. This study investigated the impact of PrP(C)-expressing exosomes on colorectal cancer cell behavior and tumor progression. The findings suggest that targeting PrP(C) in hypoxic exosomes during chemotherapy could be an effective therapeutic strategy for colorectal cancer.
Article
Environmental Sciences
Yuzhuo Chen, Zhirong Yang, Xingqiang He, Wanglong Zhu, Yujun Wang, Jiaofeng Li, Zhengyu Han, Jie Wen, Wei Liu, Yuhan Yang, Kun Zhang
Summary: Proanthocyanidins (PC) have powerful antioxidant and anti-aging effects, and play an important role in tumor cell growth, drug resistance, recurrence, and metastasis. Recent studies have found that PC exhibits inhibitory effects on colorectal cancer stem cells (CSCs) through the Wnt/β-catenin pathway.
ENVIRONMENTAL TOXICOLOGY
(2023)
Review
Oncology
Manqiu Ding, Yongqiang Chen, Yue Lang, Li Cui
Summary: Prion protein has two isoforms, PrP(C) and PrPSc. PrPSc is the pathological aggregated form that plays a role in neurodegenerative diseases, while PrP(C) is a membrane-anchored protein expressed in neurons and peripheral organs. Studies have revealed the involvement of PrP(C) in various aspects of cancer biology.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Roland Abi Nahed, Hasan Safwan-Zaiter, Kevin Gemy, Camille Lyko, Melanie Boudaud, Morgane Desseux, Christel Marquette, Tiphaine Barjat, Nadia Alfaidy, Mohamed Benharouga
Summary: This review summarizes the variance of expression of cellular prion protein (PrP (c)) in different types of cancers and discusses its roles in their development and progression, as well as its use as a potential target to treat such cancers.
Article
Biochemistry & Molecular Biology
Laia Lidon, Laura Llao-Hierro, Mario Nuvolone, Adriano Aguzzi, Jesus avila, Isidro Ferrer, Jose Antonio del Rio, Rosalina Gavin
Summary: Through research on AD patient samples and mouse models, it was found that there is a parallel association between PrPC and the 4R isoforms of tau protein. Reducing or eliminating PrPC levels leads to an increase in the balance of tau protein 3R/4R.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Adriana Limone, Valentina Maggisano, Daniela Sarnataro, Stefania Bulotta
Summary: The cellular prion protein (PrPC) is involved in prion diseases and is found overexpressed in solid tumors. Recent studies have revealed an emerging role for PrPC in cancer associated processes, especially its binding to the laminin receptor RPSA. Understanding the role of the PrPC/RPSA interaction in tumor development and response to treatment is crucial for discovering new biomarkers and therapeutic targets.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Review
Oncology
Jinjin Chu, Xianzhu Fang, Zhonghou Sun, Linlin Gai, Wenqing Dai, Haibo Li, Xinyi Yan, Jinke Du, Lili Zhang, Lu Zhao, Donghua Xu, Shushan Yan
Summary: Colorectal cancer is a prevalent cancer worldwide with increasing morbidity and mortality. Anti-epidermal growth factor receptor monoclonal antibodies have shown significant improvement in survival outcomes for metastatic colorectal cancer patients, however, resistance to these antibodies is common. Non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, have been found to play important roles in the development of drug resistance in colorectal cancer. Understanding the mechanisms of these non-coding RNAs may provide new insights for the development of molecular targets and prognostic markers in colorectal cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Xiaoyu Wu, Ming Liu, Tian Yan, Zefan Wang, Wenhua Yu, Quan Du, Wei Hu, Yongke Zheng, Zuyong Zhang, Keyi Wang, Xiaoqiao Dong
Summary: Elevated plasma PRPC levels are significantly associated with disease severity and poor 90-day outcome in ICH patients, indicating that plasma PRPC may be used as a potential prognostic biomarker after ICH.
FRONTIERS IN NEUROLOGY
(2022)
Review
Oncology
Celine Hervieu, Niki Christou, Serge Battu, Muriel Mathonnet
Summary: This review highlights the significance of colorectal cancer stem cells (CCSCs) in tumor growth, therapy resistance, and metastasis, while also discussing the methods for isolating and characterizing them, as well as ongoing clinical trials targeting CCSCs. The complexity of studying CSCs in CRC poses challenges in developing effective treatments that address therapy resistance and tumor initiation.
Article
Biochemistry & Molecular Biology
Chih-Chao Yang, Fei-Chi Chuang, Chia-Lo Chang, Chi-Ruei Huang, Hong-Hwa Chen, Hon-Kan Yip, Yen-Ta Chen
Summary: This study found that melatonin (Mel) could enhance the suppressive effects of cisplatin on bladder cancer (BC) cells by inhibiting cellular prion protein (PrPC)-mediated cell stress and proliferation signaling. The expression of PrPC was significantly increased in BC patients. Treatment with Mel or cisplatin inhibited the viability, wound healing ability, and migration rate of BC cells. These findings suggest that the inhibition of PrPC expression by Mel and cisplatin can effectively suppress the growth and proliferation of BC cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Elmira Gheytanchi, Marzieh Naseri, Feridoun Karimi-Busheri, Fatemeh Atyabi, Ensie Sadat Mirsharif, Mahmood Bozorgmehr, Roya Ghods, Zahra Madjd
Summary: The study aimed to assess the capability of HT-29 and Caco-2 cell lines in generating spheroids with CSC-related features and detailed morphological and molecular characteristics. Both cell lines formed CSCs-enriched spheroids, identified by their ability to serial sphere formation, up-regulation of stemness genes, and increased expression of CRC-CSC markers. The spheroid culture model without special scaffold/biochemical proved to be a robust, reproducible, simple, and cost-effective method for in vitro research of CRC-CSCs, including self-renewal, drug resistance, and invasion.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Qi Cheng, Hao Zheng, Ming Li, Hongyi Wang, Xiaoxiao Guo, Zhibo Zheng, Chuyan Chen, Jinming Liu, Tiancheng Zhan, Zhaowei Li, Hao Wu, Jingdong Han, Lei Liu, Tieshan Tang, Quan Chen, Lei Du
Summary: Cancer stem cells (CSCs) are a subpopulation of cancer cells that drive tumor progression and metastasis. This study reports the cooperative role of LGR4 with CD44 and PrPc in defining the stemness characteristics and metastatic capacity of colorectal CSCs. Targeting LGR4 and PrPc with lentiviral shRNAs inhibits tumor growth by inhibiting Wnt/beta-catenin signaling.
Article
Biology
Lidan Hou, Yichao Hou, Yu Liang, Baiyu Chen, Xintian Zhang, Yu Wang, Kun Zhou, Ting Zhong, Bohan Long, Wenjing Pang, Lei Wang, Xu Han, Linjing Li, Ci Xu, Isabelle Gross, Christian Gaiddon, Wei Fu, Han Yao, Xiangjun Meng
Summary: A specific peptide that targets SLC1A5 in colorectal cancer cells has been identified and conjugated with camptothecin, showing selective cytotoxicity in preclinical models.
COMMUNICATIONS BIOLOGY
(2022)
Article
Cell Biology
Rafael Rivas-Santisteban, Iu Raich, David Aguinaga, Carlos A. Saura, Rafael Franco, Gemma Navarro
Summary: The study discovered a direct interaction between PrPC and NMDAR, which alters the functionality of the receptor. Significant overexpression of NMDAR-PrPC complexes was observed in the AD model, and PrPC exacerbates the axonal transport of Tau and pTau proteins.
